High-Risk Myeloma at Consolidation: The Trial That Found Benefit Is the One That Actually Looked for It
A large, unselected trial found no benefit to a second transplant. A smaller, risk-stratified one found real benefit in exactly her cytogenetic subgroup. Both are true at once.
Louise F., a 59-year-old retired librarian, was diagnosed with multiple myeloma four months ago after a routine bloodwork abnormality led to a bone marrow biopsy she says she still can't quite believe followed from something that ordinary. FISH testing on her marrow showed a deletion of chromosome 17p — a well-established high-risk marker associated with shorter remissions and worse survival across nearly every myeloma treatment era studied. She completed induction with bortezomib, lenalidomide, and dexamethasone, achieving a very good partial response, and is now ready for autologous stem cell transplant consolidation. The question in front of the team is whether she should receive one transplant or two.
The two largest trials that have tried to answer this question reached different conclusions, and the difference isn't a contradiction so much as a reflection of who each trial actually studied. StaMINA, Stadtmauer's United States trial of 758 patients, found no significant progression-free or overall survival benefit to a second, tandem transplant over a single transplant plus lenalidomide maintenance — but only 24% of the patients it randomized had high-risk disease, so its headline result is largely a statement about patients unlike Louise. EMN02, Cavo's European trial, was both larger and reported later, and found a real progression-free survival benefit to tandem transplant within its high-risk cytogenetic subgroup — the group Louise's del17p places her in. The detail that makes this less of a standoff than it looks: StaMINA's own long-term as-treated analysis, published after the primary result, found 6-year progression-free survival of 43.6% with tandem transplant against 26% with a single transplant in its high-risk patients. The two trials disagree about the average myeloma patient. About Louise's kind of myeloma they point the same direction, and the honest caveat is not that the trials conflict but that both high-risk findings are subgroup findings, one of them as-treated rather than intention-to-treat, in a trial where over a third of the tandem arm never received the second transplant.
There is a further wrinkle in how neatly she fits the subgroup being argued over. The same FISH panel was negative for t(4;14) and t(14;16), the other two lesions bundled with del17p under the shared high-risk label, so her adverse-risk designation rests on one abnormality rather than a combination — and both trials analyzed high-risk cytogenetics as a single combined category rather than reporting del17p on its own. The subgroup she is being placed in on the strength of one marker was never a del17p subgroup. Her renal function and marrow reserve remain strong enough four months after diagnosis that a second stem cell collection, if tandem transplant is chosen, would not itself be the limiting factor in that decision.
Choosing a consolidation strategy for high-risk cytogenetics
Cavo's EMN02 analyzed outcomes by cytogenetic risk, and within its high-risk subgroup tandem transplant produced a real progression-free survival benefit over a single transplant. And I'd add the part people skip: StaMINA is usually quoted against that, but StaMINA's own long-term as-treated analysis found 6-year progression-free survival of 43.6% versus 26% in its high-risk patients — the same direction. The trial everyone cites as the negative one is not negative in Louise's subgroup. I'd give her the second transplant her own biology is telling us she's more likely to benefit from.
I'd push back on how you're using StaMINA's high-risk number, because that figure is as-treated, not intention-to-treat. Over a third of the patients randomized to the tandem arm never got the second transplant, and the ones who did were by definition the ones well enough to get it. An as-treated comparison in that setting is partly measuring who stayed fit, not what the second transplant did. StaMINA's actual randomized result was null. And EMN02's high-risk finding, real as it is, still hasn't been confirmed by a trial designed for high-risk patients from the start — which is exactly what the ASTCT panel said when it declined to recommend tandem transplant on the strength of these two trials and called for a prospective study instead.
A second transplant isn't a free option if we're wrong to give it: further cytopenias, real infection risk, and a small but genuine long-term risk of treatment-related myelodysplasia from the cumulative alkylator exposure. I'd rather not pay that cost twice on the strength of a subgroup result and an as-treated analysis, neither of which was the question either trial was powered to answer.
Both of you are reading real evidence in a direction that makes sense given what each trial actually measured. I'd propose we don't have to fully resolve which trial describes her better before doing anything — next-generation flow cytometry at day+100 can tell us directly whether her single transplant achieved MRD-negativity or not, which is more specific information about her disease right now than either trial's population-level result.
If she's MRD-positive at day+100, that's a real, individual signal that her disease hasn't been fully controlled, and a second transplant would be justified by her own residual disease, not by cytogenetics alone. If she's MRD-negative, I'd be far more comfortable proceeding to maintenance alone and revisiting only if that status changes.
Agreed: proceed to a single autologous transplant now, followed by lenalidomide maintenance, with the tandem-transplant decision explicitly deferred to day+100 next-generation flow cytometry rather than committed to upfront based on her cytogenetics alone.
Not agreed, and left unresolved rather than settled by the plan itself: whether an MRD-guided approach is genuinely the right framework for a high-risk patient, or whether it risks under-treating her by waiting for a signal that arrives only after the first transplant's window for tandem consolidation has, in practice, already mostly closed. The medical oncologist would still have preferred giving the second transplant upfront on the strength of her cytogenetics; the transplant physician viewed the MRD checkpoint as the more defensible use of a real but unconfirmed subgroup finding. The plan proceeds; the disagreement about which trial should have carried more weight for her specifically does not.